ライフサイエンスコーパス: nuclear factor

1 5145, directly alters the binding site for a nuclear factor.

2 the expression of regulatory cytoplasmic and nuclear factors.

3 g B and lethal-7 expression and high hepatic nuclear factor 1 alpha activity.

4 egulated pathways associated with hepatocyte nuclear factor 1 homeobox A (Hnf1a) and hepatocyte nucle

5 ased on inactivating mutations in hepatocyte nuclear factor 1A, activating mutations in beta-catenin,

6 ased on inactivating mutations in hepatocyte nuclear factor 1A, activating mutations in beta-catenin,

7 Variants in HNF1A encoding hepatocyte nuclear factor 1alpha (HNF-1A) are associated with matur

8 nteraction of Akt2 signaling with hepatocyte nuclear factor 1alpha (HNF1alpha) and PPARgamma, transcr

9 The transcription factor hepatocyte nuclear factor 1beta (HNF1beta) is ubiquitously overexpr

10 Hepatocyte nuclear factor 1beta (HNF1beta)-associated disease is a

11 e evaluated the potential role of hepatocyte nuclear factor-1beta (HNF-1beta) in regulating PPARGC1A

12 The transcription factor hepatocyte nuclear factor-1beta (HNF-1beta) is essential for normal

13 ding the shelterin proteins TRF1-interacting nuclear factor 2 (TIN2) and adrenocortical dysplasia hom

14 Hepatocyte nuclear factor 4 (HNF4) is the most ancient family of nu

15 We present a model of hepatocyte nuclear factor 4 (Hnf4)-induced lipotoxicity and accumul

16 Elevated HGF induced hepatocyte nuclear factor 4 alpha (Hnf4a), which competed with NK2

17 ned functional gene regulation by hepatocyte nuclear factor 4 alpha (HNF4alpha), whereas fibrotic mat

18 Hepatocyte nuclear factor 4-alpha (HNF4alpha) is a well established

19 r factor 1 homeobox A (Hnf1a) and hepatocyte nuclear factor 4A (Hnf4a), known modifiers of bile acid

20 which was down-regulated in mouse hepatocyte nuclear factor 4A knockout mice; were early-stage tumors

21 nted 29% of all HCCs; expressed a hepatocyte nuclear factor 4A-driven gene network, which was down-re

22 r genome, and are co-recruited by hepatocyte nuclear factor 4alpha (HNF4alpha).

23 al triglyceride transfer protein via hepatic nuclear factor 4alpha and chicken ovalbumin upstream pro

24 e hepatocyte transcription factor hepatocyte nuclear factor 4alpha by modulating its activation and r

25 rward loop between miR-337-3p and hepatocyte nuclear factor 4alpha.

26 Down-regulation of hepatocyte nuclear factor-4alpha expression and defective zonation

27 Reduced hepatocyte nuclear factor-4alpha was associated with activation of

28 ranscriptional factors, including hepatocyte nuclear factor-4alpha, that is early down-regulated and

29 ranscriptional activators (STAT5, hepatocyte nuclear factor 6 [HNF6], FOXA1, and FOXA2) and transcrip

30 ression; however, the complete repertoire of nuclear factors affecting these genomic changes is not k

31 enes and their functional replacement by new nuclear factors are important in models for the origin o

32 Levels of neutrophil elastase (NE) and the nuclear factors CCAAT/enhancer-binding protein alpha (C/

33 small blood capillary, chromatin density and nuclear factors could in principle be physically perturb

34 ocalized to cytosolic stress granules, where nuclear factors dock to compensate RNA pathology.

35 Our work has pointed to nuclear factor E2-related factor 2 (Nrf2) being a modula

36 ere, we identified ARF as a key regulator of nuclear factor E2-related factor 2 (NRF2) through comple

37 ctivity is associated with the activation of nuclear factor-E2-related factor 2 (Nrf2), a key anti-in

38 Locally concentrated nuclear factors ensure efficient binding to DNA template

39 ives also stimulated the expression of NRF2 (nuclear factor erythroid 2 [NF-E2]-related factor 2) and

40 e identify the ER-bound transcription factor nuclear factor erythroid 2 related factor-1, Nrf1/Nfe2L1

41 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF

42 We determined if activating nuclear factor erythroid 2-related factor (Nrf2), a pote

43 ICAM) (P < 0.001, respectively) and improved nuclear factor erythroid 2-related factor 2 (Nrf2) and h

44 tified an increased nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) in th

45 ivating the aryl hydrocarbon receptor (AhR), nuclear factor erythroid 2-related factor 2 (Nrf2), and

46 cancer cells attenuated GSH/GSSG, total GSH, nuclear factor erythroid 2-related factor 2 (Nrf2), and

47 Nuclear factor erythroid 2-related factor 2 (Nrf2), the

48 vels of estrogen receptor-alpha activity and nuclear factor erythroid 2-related factor 2 activity, an

49 ctivator of p62 through competition of Nrf2 (nuclear factor erythroid 2-related factor 2) for Keap1 b

50 Notably, expression of nuclear factor erythroid 2-related factor 2-dependent an

51 Nuclear factor erythroid-2-related factor 1 (NRF1) and N

52 KEAP1), which targets transcriptional factor nuclear factor erythroid-2-related factor 2 (NRF2) for d

53 Nuclear factor erythroid-2-related factor 2 (Nrf2) is a

54 ancer cell lines via focal amplification and nuclear factor erythroid-2-related factor 2 (NRF2)-media

55 r advanced glycation end products (RAGE) via nuclear factor erythroid-2-related-factor-2 (Nrf2)-depen

56 ated with impaired glutathione synthesis and nuclear factor erythroid-derived 2 related factor 2 (NRF

57 ung fibroblasts is inhibited by silencing of nuclear factor erythroid-derived 2-like 2 (Nrf2), suppor

58 iron levels by binding to and deacetylating nuclear factor erythroid-derived 2-related factor 2 (NRF

59 d with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased

60 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a

61 Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is th

62 rt therapeutic effects via activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathw

63 he basic leucine zipper transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) plays

64 t significantly affected genes belong to the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) trans

65 ulator of the cellular antioxidant response, nuclear factor (erythroid-derived 2)-like 2 (NRF2), shut

66 Activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), the

67 Nuclear factor (erythroid-derived 2)-like 2 and its Caen

68 The transcription factor NRF2 (nuclear factor [erythroid-derived 2]-like 2) plays cruci

69 n gene transcription by activating the NRF2 (nuclear factor [erythroid-derived 2]-like 2) transcripti

70 validated a difference in the regulation of nuclear factor, erythroid 2 (Nfe2) and core-binding fact

71 sk tumors were characterized by up-regulated nuclear factor, erythroid 2-like 2 activity; high lin-28

72 The activity of the transcription factor nuclear factor-erythroid 2 p45-derived factor 2 (NRF2) i

73 Wild-type (Control) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) n

74 We went on to identify the AMPK-nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) p

75 e mediated by heat shock factor 1 (HSF1) and nuclear factor-erythroid 2 p45-related factor 2 (NRF2),

76 response, we examined here the expression of nuclear factor-erythroid 2-related factor (Nrf-2), a mas

77 This was confirmed by silencing nuclear factor-erythroid 2-related factor 2 (Nrf2), whic

78 Nuclear factor-erythroid 2-related factor-2 (Nrf2) is a

79 so induced expression of the redox regulator nuclear factor-erythroid-derived 2-like 2 (NFE2L2 alias

80 In this study, silencing the expression of a nuclear factor gene, CmNF-YB8, from the short day plant

81 The hepatocyte nuclear factor (HNF) family regulates complex networks o

82 assified into 14 inflammatory, 20 hepatocyte nuclear factor (HNF)-1alpha-mutated, one beta-catenin-ac

83 ssion of its key transactivators, hepatocyte nuclear factor (HNF)-4alpha and HNF6.

84 The nuclear factor I (NFI) family of transcription factors p

85 The discovery of the unique role of Nfic (nuclear factor I C; a transcriptional factor) in control

86 differentiation-related transcription factor nuclear factor I-A (NFI-A) controls MDSC expansion durin

87 /Notch-like EGF repeat containing (Dner) and nuclear factor I/A (Nfia), that are each heavily express

88 Disruption of nuclear factor IA (NFIA), nuclear factor IB (NFIB), or n

89 Disruption of nuclear factor IA (NFIA), nuclear factor IB (NFIB), or nuclear factor IX (NFIX) re

90 ne biotinylation, and its participation as a nuclear factor in chromatin dynamics.

91 ctor IA (NFIA), nuclear factor IB (NFIB), or nuclear factor IX (NFIX) results in abnormal development

92 ecific lipin-1 deficiency diminished hepatic nuclear factor kappa B (NF-kappaB) activity, limited liv

93 The transcription factor nuclear factor kappa B (NF-kappaB) and the long non-codi

94 Nuclear factor kappa B (NF-kappaB) is an inducible trans

95 MRV miRNAs, we screened for their effects on nuclear factor kappa B (NF-kappaB) signaling in the pres

96 biquitinated chains from key proteins in the nuclear factor kappa B (NF-kappaB) signaling pathway.

97 Here we demonstrate that the dynamics of Nuclear Factor kappa B (NF-kappaB) signalling and the ce

98 decrease in PKC activity, and inhibition of nuclear factor kappa B (NF-kB) translocation, were attri

99 in terms of interleukin (IL)-8 promoter and nuclear factor kappa B (NFkappaB) activity, were observe

100 IkappaBalpha enhances the rate of release of nuclear factor kappa B (NFkappaB) from DNA target sites

101 n (EMT), but also constitutive activation of nuclear factor kappa B (NFkappaB; RELA).

102 nate attenuated the HS-induced activation of nuclear factor kappa B and reduced the expression of pro

103 nate attenuated the HS-induced activation of nuclear factor kappa B and reduced the expression of pro

104 ylated and thereby inhibited by inhibitor of nuclear factor kappa B kinase subunit beta (IKKbeta) to

105 Blocking phosphorylation of nuclear factor kappa B p65 on Ser536 inhibited the emerg

106 iated genes and drove hyperactivation of the nuclear factor kappa B p65 pathway.

107 vo that depends on Ser536 phosphorylation of nuclear factor kappa B p65; this pathway may hold valuab

108 of the mitogen-activated protein kinase and nuclear factor kappa B pathways in MDSCs was MyD88 depen

109 in the presence of antagonists of NFkappaB (nuclear factor kappa B) or iNOS activity, NO synthesis a

110 location of transcription factors, including nuclear factor kappa B, although its role in PCa was lar

111 in inflammatory and cancer pathways, such as nuclear factor kappa B, EGF, Wnt, and B-cell lymphoma 2.

112 rough regulating the activation of canonical nuclear factor kappa B, phosphatidylinositol-4,5-bisphos

113 ing LTR-driven HIV-1 gene transcription in a nuclear factor kappa B-dependent manner.

114 sponse genes, pointing to the suppression of nuclear factor kappa B-dependent transcription.

115 ulting in de novo lipogenesis, and increased nuclear factor kappa B-mediated inflammation act in conc

116 bition of glycogen synthase kinase-3beta and nuclear factor kappa B.

117 bition of glycogen synthase kinase-3beta and nuclear factor kappa B.

118 0 kDa) binds to macrophage-TLR4 and triggers nuclear factor kappa beta activation that upregulates se

119 aining, and C-X-C chemokine receptor type 4, nuclear factor kappa beta, and tartrate-resistant acid p

120 ified as a critical brake on proinflammatory nuclear factor kappa light chain enhancer of activated B

121 The nuclear factor kappa light-chain enhancer of activated B

122 that stimulation with receptor activator of nuclear factor kappa-B ligand (RANKL) resulted in a robu

123 oxidase (MPO), and the cytokine receptor for nuclear factor kappa-B ligand (RANKL) were significantly

124 ted T cells to produce receptor activator of nuclear factor kappa-B ligand (RANKL), which, in turn, p

125 tal tissue and induces receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK-osteoproteger

126 Change in circulating receptor activator of nuclear factor kappa-B ligand was higher in the interven

127 Nuclear factor kappa-light chain enhancer of activated B

128 croRNA (miR)-181a is a negative regulator of nuclear factor kappa-light-chain enhancer of activated B

129 th a defect in the capacity to phosphorylate nuclear factor kappa-light-chain-enhancer of activated B

130 o associated with reduced phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B

131 and interleukin (IL)-1alpha, that activated nuclear factor kappa-light-chain-enhancer of activated B

132 of p38 mitogen activated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B

133 Messenger RNA expression levels of nuclear factor kappa-light-chain-enhancer of activated B

134 tumorigenesis and metastasis-through a TLR4/nuclear factor kappa-light-chain-enhancer of activated B

135 Znrf4 knockdown monocytes have sustained nuclear factor kappa-light-chain-enhancer of activated B

136 atients were less capable in phosphorylating nuclear factor kappa-light-chain-enhancer of activated B

137 of p38 mitogen activated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B

138 Activation of nuclear factor-kappa (NF-kappa) B triggers proinflammato

139 The nitric oxide concentration and nuclear factor-kappa B (NF-kappaB) activity were measure

140 GF), inducible nitric oxide synthase (iNOS), nuclear factor-kappa B (NF-kappaB) and intercellular adh

141 The decline in the activation of nuclear factor-kappa B (NF-kappaB) and p38 mitogen-activ

142 affects expression of receptor activator of nuclear factor-kappa B (NF-kappaB) ligand (RANKL), a pot

143 ne of these main signaling mechanisms is the nuclear factor-kappa B (NF-kappaB) pathway, which integr

144 f myeloid cells, are partly regulated by the nuclear factor-kappa B (NF-kappaB) pathway.

145 like receptor 4 (TLR4)-dependent pathway via nuclear factor-kappa B (NF-kappaB), while simultaneously

146 s and osteoclasts, and receptor activator of nuclear factor-kappa B ligand (RANKL) activity.

147 ranscription factor-2, receptor activator of nuclear factor-kappa B ligand (RANKL), sclerostin, and D

148 interleukin-1beta and receptor activator of nuclear factor-kappa B ligand than group EP-HN019 (P <0.

149 d that overexpression of LINC00305 activated nuclear factor-kappa beta (NF-kappaB) and that inhibitio

150 Nuclear factor kappaB (NF-kappaB) activation was measure

151 and activation of the transcription factors nuclear factor kappaB (NF-kappaB) and interferon regulat

152 additional transcription factors, including nuclear factor kappaB (NF-kappaB) and signal transducer

153 aining adapter-inducing IFN-alpha (TRIF) and nuclear factor kappaB (NF-kappaB) causes the apoptosis o

154 Mechanistically, we demonstrate that nuclear factor kappaB (NF-kappaB) directly regulates the

155 unction mutations in the IKBKG gene encoding nuclear factor kappaB (NF-kappaB) essential modulator (N

156 30 years ago and is due to mutations in the nuclear factor kappaB (NF-kappaB) essential modulator, a

157 in these mice was prevented by inactivating nuclear factor kappaB (NF-kappaB) in microglia/myeloid c

158 Activation of nuclear factor kappaB (NF-kappaB) induces mesenchymal (M

159 Nuclear factor kappaB (NF-kappaB) is a family of critica

160 turn, PKR stimulates nuclear accumulation of nuclear factor kappaB (NF-kappaB) p65 species phosphoryl

161 in cancer cells, and subsequently activates nuclear factor kappaB (NF-kappaB) pathway which has a st

162 ferential enhancer utilization, and identify nuclear factor kappaB (NF-kappaB) signaling as a key pat

163 constitutive activation of pro-inflammatory nuclear factor kappaB (NF-kappaB) signaling in TNBC.

164 ly demonstrated a key role for the canonical nuclear factor kappaB (NF-kappaB) subunits, p65 and c-Re

165 way which regulates the transcription factor Nuclear Factor kappaB (NF-kappaB) using this method iden

166 nuclear factor of activated T cells (NFAT), nuclear factor kappaB (NF-kappaB), and activator protein

167 ed the pro-inflammatory transcription factor nuclear factor kappaB (NF-kappaB), whereas stable, non-o

168 g to caspase-8-mediated apoptosis as well as nuclear factor kappaB (NF-kappaB)-dependent cell surviva

169 n IkappaB, an inhibitor of the transcription nuclear factor kappaB (NF-kappaB).

170 ges and dependent on transcription driven by nuclear factor kappaB (NF-kappaB).

171 at involves activation of IkappaB kinase and nuclear factor kappaB (NF-kappaB).

172 An example is activation of nuclear factor kappaB (NF-kappaB).

173 In breast tumors, activation of the nuclear factor kappaB (NFkappaB) pathway promotes surviv

174 A2AR signaling reduces receptor activator of nuclear factor kappaB (RANK)-mediated osteoclastogenesis

175 ), one of the crucial negative regulators of nuclear factor kappaB activation in myeloid cells and DC

176 cell differentiation and is mediated through nuclear factor kappaB activation.

177 Rtp801 triggers nuclear factor kappaB and consequent inducible NOS (iNOS

178 d both mechanisms are impaired when TET2 and nuclear factor kappaB are downregulated.

179 We also found that nuclear factor kappaB contributes to KIT-dependent upreg

180 actor kappaB receptor, receptor activator of nuclear factor kappaB ligand/macrophage colony-stimulati

181 overproduced TNF and IL-6 through increased nuclear factor kappaB nuclear translocation.

182 AhR and some components of the noncanonical nuclear factor kappaB pathway were shown to be downregul

183 The CARD11 defect altered the classical nuclear factor kappaB pathway, resulting in poor in vitr

184 gher expression of the receptor activator of nuclear factor kappaB receptor, receptor activator of nu

185 ive oxygen species that, on one hand, induce nuclear factor kappaB signaling and expression of inflam

186 muscle cells by various mechanisms activates nuclear factor kappaB signaling and increases expression

187 tion of endothelial autophagy and attenuated nuclear factor kappaB signaling in vitro and in vivo.

188 immunodeficiency caused by mutations in the nuclear factor kappaB signaling pathway (IKBKG and NFKBI

189 es reactive oxygen species levels, activates nuclear factor kappaB signaling, and increases AngII rec

190 reactive oxygen species and increased basal nuclear factor kappaB signaling, leading to an increase

191 Treatment with AZD8835 induced inhibition of nuclear factor kappaB signaling, prompting us to combine

192 Tet methylcytosine dioxygenase 2 (TET2) and nuclear factor kappaB to DNA demethylation was tested by

193 activator of transcription 3) and NFkappaB (nuclear factor kappaB), the pro-inflammatory and cancer-

194 t activate IFN regulatory factors (IRFs) and nuclear factor kappaB.

195 mechanism of action correlated with reduced nuclear factor-kappaB (NF-kappaB) activation and decreas

196 We purified nuclear extracts and quantified nuclear factor-kappaB (NF-kappaB) activation and DNA bin

197 SP110b modulates nuclear factor-kappaB (NF-kappaB) activity, resulting in

198 horylation and subsequent activation of both nuclear factor-kappaB (NF-kappaB) and mechanistic target

199 OT in human amnion; atosiban alone activates nuclear factor-kappaB (NF-kappaB) and mitogen activated

200 Nuclear factor-kappaB (NF-kappaB) is a family of transcr

201 rantly overexpressed in NSCLC, activates the nuclear factor-kappaB (NF-kappaB) p65-->ZEB1 pathway and

202 an early-primary response gene controlled by nuclear factor-kappaB (NF-kappaB) signaling in murine ma

203 We have shown that both Wnt and nuclear factor-kappaB (NF-kappaB) signaling were boosted

204 ists stems from TLR5-dependent activation of nuclear factor-kappaB (NF-kappaB) that mediates innate a

205 inflammatory responses through activation of nuclear factor-kappaB (NF-kappaB), has been implicated a

206 ty with concomitant nuclear translocation of nuclear factor-kappaB (NF-kappaB), indicating that NF-ka

207 ceptor cooperativity with factors, including nuclear factor-kappaB (NF-kappaB), may enhance regulator

208 utive activation of the transcription factor nuclear factor-kappaB (NF-kappaB), which controls expres

209 hown to direct gene expression by regulating nuclear factor-kappaB (NF-kappaB)-mediated inflammatory

210 The interaction of ELF3 and nuclear factor-kappaB (NFkappaB) in modulating LCN2 leve

211 of LCN2 expression and its cooperation with nuclear factor-kappaB (NFkappaB).

212 and activator of transcription 3 (STAT3) and nuclear factor-kappaB activation in response to the bact

213 ammation and lung injury in vivo and reduced nuclear factor-kappaB activation predominantly by inhibi

214 ia across the apical epithelial barrier, (3) nuclear factor-kappaB activation, (4) accumulation of ma

215 der normocapnia or hypercapnic acidosis, and nuclear factor-kappaB activation, animal survival, lung

216 epithelial morphology, SIgA, bacterial DNA, nuclear factor-kappaB activation, neutrophil and macroph

217 iferation, migration, monocyte adhesion, and nuclear factor-kappaB activation.

218 By linking IKKbeta-mediated nuclear factor-kappaB activity with GLI1, we identified

219 ponse gene 88 (MyD88) pathway that activates nuclear factor-kappaB and increases monocyte chemotaxis.

220 upon antigen receptor-induced activation of nuclear factor-kappaB and mammalian target of rapamycin

221 subtype that showed increased sensitivity to nuclear factor-kappaB and mitogen-activated protein kina

222 matory endotoxin lipopolysaccharide via both nuclear factor-kappaB and signal transducer and activato

223 atory cytokines with or without aldosterone, nuclear factor-kappaB inhibitor BAY 11-7082, or plasma f

224 ge, and protein expression of the endogenous nuclear factor-kappaB inhibitor).

225 Although nuclear factor-kappaB is activated in cells from patient

226 = 0.003), and soluble receptor activator of nuclear factor-kappaB ligand (sRANKL) concentrations wer

227 c sensitization to the receptor activator of nuclear factor-kappaB ligand and increased osteoblastic

228 -selectin, fibrinogen, receptor activator of nuclear factor-kappaB ligand, high-sensitivity C-reactiv

229 , the repressor of the receptor activator of nuclear factor-kappaB ligand-mediated osteoclastogenesis

230 )IgM(+)) with active B cells (phosphorylated nuclear factor-kappaB p65(+)), proliferation markers (Ki

231 pha in microglia, and the recruitment of the nuclear factor-kappaB pathway while restoring hypothalam

232 Mechanistically, Nrp1 deletion activates the nuclear factor-kappaB pathway, which in turn accentuates

233 within 5 hours in human vascular cells in a nuclear factor-kappaB pathway-dependent manner.

234 transducer and activator of transcription 3/nuclear factor-kappaB pathway.

235 rrest through inhibiting the activity of the nuclear factor-kappaB pathway.

236 one marrow-derived macrophages by activating nuclear factor-kappaB signaling and reactive oxygen spec

237 med that clofibrate abrogates the binding of nuclear factor-kappaB to the PTPRZ1 and Wnt8a promoters,

238 Adelmidrol treatment, moreover, reduced nuclear factor-kappaB translocation, cyclooxygenase-2, a

239 opathy, characterized by elevated NF-kappaB (nuclear factor-kappaB) activation and TNF (tumor necrosi

240 q are common and include genes that modulate nuclear factor-kappaB, BCL2, BTK, apoptosis, differentia

241 ion of SMAD6, which required the activity of nuclear factor-kappaB, but not transforming growth facto

242 extravascular albumin), and immunoblotting (nuclear factor-kappaB, hypoxia-inducible factor-1alpha,

243 at infection with HCV leads to activation of nuclear factor-kappaB, resulting in increased expression

244 UMA, whereas inhibition of mTORC2 results in nuclear factor-kappaB-mediated expression of the Early G

245 metallopeptidase 2 via transcription factor nuclear factor-kappaB.

246 ne expression independently of activation of nuclear factor-kappaB.

247 r signal-regulated kinase, sphingolipid, and nuclear factor-kappaB.

248 mplicated in DMD-related pathways, i.e., the nuclear-factor-kappaB and TGFbeta pathways.

249 dependent of Tpl2 kinase, a key regulator of nuclear factor kappaB1-mediated MAPK activation in macro

250 ere we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclas

251 IL-1beta production, IL-1beta secretion and nuclear factor-kB activity were reduced by knocking down

252 cells were able to induce Ca(2+) influx and nuclear factor (NF) kappaB signaling, whereas extracellu

253 sion of Toll-like receptor (TLR)2, TLR4, and nuclear factor (NF)-kappa B mRNA levels were analyzed us

254 cell activation was evaluated by quantifying nuclear factor (NF)-kappa B-p65 and cytokine expression

255 ased lymphocytic infiltration, and decreased nuclear factor (NF)-kappaB activation compared with cont

256 , downregulation of Bcl-xL levels, decreased nuclear factor (NF)-kappaB activity, and apoptosis.

257 iRNA that inhibits multiple factors from the nuclear factor (NF)-kappaB pathway in various cell types

258 constitutive activation of the noncanonical nuclear factor (NF)-kappaB pathway.

259 and upregulated miR-19a can in turn activate nuclear factor (NF)-kappaB signaling and TNF-alpha produ

260 -1180 directly targets key inhibitors of the nuclear factor (NF)-kappaB signaling pathway (i.e., OTUD

261 ts neuroprotection by up-regulating c-REL, a nuclear factor (NF)-kappaB subtype that, in turn, enhanc

262 exposed to microbial stimuli, DCs activated nuclear factor (NF)-kappaB, which induced expression of

263 Kanglaite inhibited the expression of nuclear factor (NF)-kappaBeta and upregulated that of co

264 translocation of transcription factors from Nuclear Factor (NF)-kB and Interferon Regulatory Factor

265 Transcription factors of the nuclear factor of activated T cell (NFAT) family are ess

266 tabolic regulators through the activation of nuclear factor of activated T cells (NFAT) and the PI3K-

267 osphatase required for the activation of the nuclear factor of activated T cells (NFAT) family of tra

268 The nuclear factor of activated T cells (NFAT) family protei

269 ut had no effect on G1-mediated signaling to nuclear factor of activated T cells (NFAT) luciferase.

270 ites is strongly involved in CaV1.2-mediated nuclear factor of activated T cells (NFAT) signaling, lo

271 Calcineurin/nuclear factor of activated T cells (Nfat) signaling, wh

272 itogenic effect of Ex-4 requires calcineurin/nuclear factor of activated T cells (NFAT) signaling.

273 ignaling activates the transcription factors nuclear factor of activated T cells (NFAT), nuclear fact

274 ulatory factor 4 (IRF4) mRNA expression, and nuclear factor of activated T cells (NFAT1) protein expr

275 ment and its substrate transcription factor, nuclear factor of activated T cells (NFAT4), appear in a

276 have identified an autocrine pathway linking nuclear factor of activated T cells 2 (NFAT1), autotaxin

277 CaMKIV) activation, and interactions between nuclear factor of activated T cells 3 (NFATc3) and FosB

278 ion of the CN-dependent transcription factor nuclear factor of activated T cells 4 (NFAT4).

279 that the osmoprotective transcription factor nuclear factor of activated T cells 5 (NFAT5) critically

280 Activation of calcineurin-dependent nuclear factor of activated T cells c1 (NFATc1) is conve

281 in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering

282 cium signaling, cytosolic calcium activating nuclear factor of activated T cells translocation direct

283 phage colony-stimulating factor induction of nuclear factor of activated T cells type c-1 and catheps

284 of the osteoclast transcriptional activator nuclear factor of activated T cells type c-1, associated

285 GF), E-cadherin, SRY-box 7 (SOX7), and NFAT (nuclear factor of activated T cells) kinase dual-specifi

286 hat cooperates with the transcription factor nuclear factor of activated T cells, c1 (NFATc1) to driv

287 t to be mediated by the transcription factor nuclear factor of activated T cells, cytoplasmic 1 (NFAT

288 at suppresses the expression and activity of nuclear factor of activated T cells, cytoplasmic, calcin

289 ent (MAPK, JNK) and non-catalytic-dependent (nuclear factor of activated T cells, NFAT) VAV1 effector

290 Finally, we found that nuclear factor of activated T-cell (NFAT) activity is pr

291 ined the effects of CEFIP on the calcineurin/nuclear factor of activated T-cell (NFAT) pathway.

292 We sought to investigate canonical nuclear factor of kappa light chain (NF-kappaB) signalin

293 a result of lowered inhibitory IkappaBalpha (nuclear factor of kappa light polypeptide gene enhancer

294 eus accumbens-associated protein-1 (NAC1), a nuclear factor of the BTB/POZ gene family, has emerging

295 6) and/or c-fos signaling to induce NFATc1 (nuclear factors of activated T cells, cytoplasmic 1).

296 Starting from the hypothesis that nuclear factors that bind to genomic regions with SCS co

297 We have identified a large set of candidate nuclear factors that may underpin immunity to pathogens

298 associated with an astonishing collection of nuclear factors, which serve to not only store the nucle

299 ociated protein Basp1, thereby de-repressing nuclear factors WT1, Esrrb and Lin28a (Lin28) independen

300 Nuclear Factor Y (NF-Y) is a heterotrimeric transcriptio